Kalibala, D., Nabaggala, C., Turyagyenda, L., Mboizi, V., Naggayi, S. K., Kabatabaazi, M., Rosano, C., Munube, D., Kasirye, P., Ssenkusu, J., Opoka, R., Bangirana, P., Green, N. S., Idro, R., & Mupere, E. (2023). Effect of Hydroxyurea Treatment on Body Composition in Children with Sickle Cell Anemia in Uganda Using Bioelectrical Impedance Analysis (BIA). Blood, 142(Supplement 1), 1136–1136. https://doi.org/10.1182/blood-2023-190181

De, A., Jung, K. hwa, Davis, H., Siddiqui, A., Kattan, M., Quinn, J., Rundle, A. G., Lovinsky-Desir, S., & Green, N. S. (2023). Effects of Air Pollution on Respiratory Events and Pain Crises Among Children with Sickle Cell Disease in New York City. Blood, 142(Supplement 1), 5298–5298. https://doi.org/10.1182/blood-2023-189540

Dhodapkar, M. V., Alsina, M., Berdeja, J. G., Patel, K. K., Richard, S., Vij, R., Leleu, X., Egan, D. N., Bergsagel, P. L., Reshef, R., Usmani, S. Z., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Eliason, L., Zhong, X., Greggio, C., Tran, S., … Siegel, D. S. (2023). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up. Blood, 142(Supplement 1), 2101–2101. https://doi.org/10.1182/blood-2023-173970

Tashi, T., Hermine, O., Castells, M., Guilarte, M., Sabato, V., Maurer, M., Panse, J., Alvarez-Twose, I., Cabral, R., Bird, R., Barete, S., Bouillet, L., Hermans, M., Van Daele, P., González-De-Olano, D., Griffiths, E. A., Jurcic, J., Dybedal, I., Damaj, G. L., … Livideanu, C. B. (2023). Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial. Blood, 142(Supplement 1), 76–76. https://doi.org/10.1182/blood-2023-188904

Hughes, M. S., Leng, S., Chakraborty, R., Bhutani, D., Mapara, M., Raza, S., & Lentzsch, S. (2023). Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up. Blood, 142(Supplement 1), 6576–6576. https://doi.org/10.1182/blood-2023-182842

Pazos, M., Estrella, B., Piorczynski, T. B., Tolu, S. S., Huang, W., Ryu, Y. K., & Amengual, J. E. (2023). First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL. Blood, 142(Supplement 1), 4184–4184. https://doi.org/10.1182/blood-2023-186639

Akahoshi, Y., Spyrou, N., Weber, D., Aguayo-Hiraldo, P., Ayuk, F. A., Bunworasate, U., Choe, H., Eder, M., Etra, A., Grupp, S., Hexner, E. O., Hogan, W. J., Kitko, C. L., Kraus, S., Merli, P., Qayed, M., Reshef, R., Schechter-Finkelstein, T., Ullrich, E., … Nakamura, R. (2023). Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study. Blood, 142(Supplement 1), 776–776. https://doi.org/10.1182/blood-2023-181900

Kim, T. O., Geris, J. M., Grimes, A. B., Grace, R. F., Lambert, M. P., Rose, M. J., Shimano, K. A., Niss, O., Neunert, C., Nakano, T. A., Macmath, D., Dinu, B., Kirk, S. E., Despotovic, J. M., Flanagan, J. M., & Scheurer, M. E. (2023). Genetic Variants in Canonical Wnt Signaling Pathway Associated with Pediatric ITP. Blood, 142(Supplement 1), 2593–2593. https://doi.org/10.1182/blood-2023-175013

Green, N. S., Manwani, D., Aygun, B., Appiah-Kubi, A., Smith-Whitley, K., Jia, H., & Smaldone, A. (2023). Habit Efficacy Trial: A Multi-Site Randomized Controlled Trial of Community Health Worker Support to Increase Hydroxyurea Adherence of Youth with Sickle Cell Disease. Blood, 142(Supplement 1), 3901–3901. https://doi.org/10.1182/blood-2023-190031

Hoffman, J. E., Bumma, N., Richter, J., Dhodapkar, M. V., Lee, H. C., Suvannasankha, A., Houde, C. A., Maly, J. J., Shah, M. R., Baz, R., Namburi, S., Wu, K. L., Pianko, M., Ye, J. C., Lentzsch, S., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Jagannath, S. (2023). Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment. Blood, 142(Supplement 1), 3359–3359. https://doi.org/10.1182/blood-2023-179170

Muchtar, E., Palladini, G., Schonland, S., Dispenzieri, A., Wisniowski, B., Merlini, G., Milani, P., Hegenbart, U., Dittrich, T., Kastritis, E., Dimopoulos, M. A., Sanchorawala, V., Szalat, R. E., Liedtke, M., Gupta, M., Landau, H., Lentzsch, S., Hughes, M. S., Cibeira López, M. T., … Gertz, M. A. (2023). Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study. Blood, 142(Supplement 1), 3411–3411. https://doi.org/10.1182/blood-2023-190226

Khatiwada, P., Soni, M., & Muranski, P. (2023). Highly Active Cytotoxic CD4 + T Cells Targeting EBV Oncoproteins with Enhanced In Vivo Anti-Tumor and Self-Renewal Properties. Blood, 142(Supplement 1), 3464–3464. https://doi.org/10.1182/blood-2023-190690

Vander Haar, E., Abshier Ware, C., Allen, G., Armstrong, R., Black, D., Bombara, M., Dhanraj, D., Lawrence, L., Miller, R., Nanda, S., Paidas, M. J., Patki, K. C., Sitras, V., Skupski, D., Swarup, M., Thorp, J., Tiller, H., Verweij, J., & Bussel, J. B. (2023). Identifying Pregnancies at Higher Risk for HPA-1a Alloimmunization and Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): An International, Prospective, Natural History Study. Blood, 142(Supplement 1), 1224–1224. https://doi.org/10.1182/blood-2023-177657

Al Malki, M. M., Keyzner, A., Suh, H. C., Matin, A., Buonomo, E., Wang, Y., Abelowitz, N., Murray, J., Macbeath, G., Barton, D., Chattopadhyay, S., & Reshef, R. (2023). Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation. Blood, 142(Supplement 1), 2090–2090. https://doi.org/10.1182/blood-2023-187355

Tolu, S. S., Piorczynski, T. B., Pazos, M., Estrella, B., Huang, W., Ryu, Y. K., Cherng, H.-J. J., Pro, B., & Amengual, J. E. (2023). JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity. Blood, 142(Supplement 1), 6118–6118. https://doi.org/10.1182/blood-2023-180875

Bagot, M., Kim, Y. H., Geskin, L. J., Ortiz-Romero, P. L., Kim, E., Mehta-Shah, N., Dereure, O., Oro, S., Beylot-Barry, M., Dalle, S., Jacobsen, E., Lansigan, F., Ram-Wolff, C., Khodadoust, M. S., Battistella, M., Gru, A. A., Moins-Teisserenc, H., Zinzani, P. L., Viotti, J., … Porcu, P. (2023). Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial. Blood, 142(Supplement 1), 185–185. https://doi.org/10.1182/blood-2023-173806

Schreidah, C. M., DeStephano, D. M., Pan, S. S., Wang, S., Shen, H., Ta, C. N., Reynolds, G. B., Fahmy, L. M., Gordon, E. R., Adeuyan, O., Kwinta, B. D., Stonesifer, C. J., Chan, W. H., Choi, J., Duvic, M., Gallardo, F., Girardi, M., Guitart, J., Kim, Y. H., … Geskin, L. J. (2023). Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma. Blood, 142(Supplement 1), 1715–1715. https://doi.org/10.1182/blood-2023-190775

Namazzi, R., Idro, R., Kalibala, D., Ssenkusu, J., Akun, P., Mboizi, V., Gondwe, T. N., Munube, D., Kasirye, P., Nabaggala, C., John, C. C., Green, N. S., Robberstat, B., Hensbroek, B. van, Kuile, F. ter, Phiri, K. S., & Opoka, R. (2023). Malaria in Children with Sickle Cell Anaemia in Areas with Low, Moderate and High Transmission in Uganda. Blood, 142(Supplement 1), 5327–5327. https://doi.org/10.1182/blood-2023-189066

Gui, G., Dillon, L. W., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., de Lima, M., Litzow, M. R., Kebriaei, P., Saber, W., … Hourigan, C. S. (2023). Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia. Blood, 142(Supplement 1), 4316–4316. https://doi.org/10.1182/blood-2023-186376

Proli, A., Sawas, A., Ho, G., Wang, J., & Fullerton, C. (2023). Methods for Identification of Blood Product Transfusions in a Cohort of Myelofibrosis Patients: An Assessment of Data Capture Using Insurance Claims and Electronic Health Record Abstraction. Blood, 142(Supplement 1), 7292–7292. https://doi.org/10.1182/blood-2023-189374

Cherng, H.-J. J., Yang, X., Yancey, R., Gordillo, C. A., Piorczynski, T. B., Chan, H. T., Ofori, K. N., Bhagat, G., Califano, A., Pro, B., Booher, K., Amengual, J. E., Reshef, R., & Sina, A. A. I. (2023). Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes. Blood, 142(Supplement 1), 4371–4371. https://doi.org/10.1182/blood-2023-178376

Shi, A., Ali, A. M., Cann, G., Shaknovich, R., Venn, O., Raza, A., & Liu, Q. (2023). Methylation Biology of a Blood-Based MDS Risk Stratification Test. Blood, 142(Supplement 1), 4599–4599. https://doi.org/10.1182/blood-2023-180256

Bernard, E., Hasserjian, R., Greenberg, P. L., Arango Ossa, J. E., Creignou, M., Nannya, Y., Tuechler, H., Medina-Martínez, J. S., Levine, M. F., Jädersten, M., Germing, U., Sanz, G., van de Loosdrecht, A. A., Kosmider, O., Follo, M. Y., Thol, F., Zamora, L., Pinheiro, R. F., Pellagatti, A., … Papaemmanuil, E. (2023). Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications. Blood, 142(Supplement 1), 997–997. https://doi.org/10.1182/blood-2023-186863

Naggayi, S. K., Kalibala, D., Opoka, R., Rosano, C., Munube, D., Kasirye, P., Mupere, E., Mboizi, V., Ssenkusu, J., Green, N. S., Idro, R., & Bangirana, P. (2023). Neurocognitive Improvement with Hydroxyurea Therapy in Children with Sickle Cell Anemia in Uganda: Interim Analysis at Month 18. Blood, 142(Supplement 1), 275–275. https://doi.org/10.1182/blood-2023-190687

Peters, D. T., Amburn, J., Tuchman, S., Lichtman, E. I., Jensen, C. E., Jain, K., Lentzsch, S., Chakraborty, R., Bhutani, D., & Rubinstein, S. M. (2023). Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance. Blood, 142(Supplement 1), 2027–2027. https://doi.org/10.1182/blood-2023-189341

Tolu, S. S., Sanjurjo, A., Destephano, D., Pro, B., & Amengual, J. E. (2023). Outcomes in Minorities with PTCL By Clinical Trial Enrollment. Blood, 142(Supplement 1), 4431–4431. https://doi.org/10.1182/blood-2023-177722

Tolu, S. S., Gribbin, C., Seshadri, M. R., Chen, Z., Orlando, E., Grenet, J., Toor, R., Sanjurjo, A., Phillips, A. A., Shore, T. B., Martin, P., Leonard, J. P., Pro, B., Amengual, J. E., & Ruan, J. (2023). Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL. Blood, 142(Supplement 1), 1698–1698. https://doi.org/10.1182/blood-2023-178231

Patel, A. A., Yoon, J. J., Johnston, H., Davidson, M. B., Viswabandya, A., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Dean, R., Kassner, J., Rampal, R. K., Guru Murthy, G. S., Bradley, T., Abaza, Y., Garcia, J. S., … Odenike, O. (2023). Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies. Blood, 142(Supplement 1), 3192–3192. https://doi.org/10.1182/blood-2023-174790

Coombs, C. C., Woyach, J. A., Brown, J. R., Ghia, P., Roeker, L. E., Patel, K., Eyre, T. A., Tam, C. S., Seymour, J. F., Shah, N. N., Flinn, I. W., Cheah, C. Y., Ma, S., Rhodes, J. M., Izutsu, K., Jurczak, W., Wierda, W. G., Loubert, A., Payakachat, N., … Lamanna, N. (2023). Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study. Blood, 142(Supplement 1), 6535–6535. https://doi.org/10.1182/blood-2023-186145

Holtan, S. G., Martens, M. J., Al Malki, M. M., Efebera, Y., Kitko, C. L., Reshef, R., Rezvani, A. R., Shaffer, B. C., Solh, M. M., Yao, J. M., Runaas, L., Elmariah, H., Larkin, K. T., El Jurdi, N. H., Gooptu, M., Loren, A. W., Hall, A. C., Alousi, A., Jamy, O., … Bolanos-Meade, J. (2023). Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation. Blood, 142(Supplement 1), 897–897. https://doi.org/10.1182/blood-2023-187859

Jagannath, S., Richter, J., Dhodapkar, M. V., Hoffman, J. E., Lee, H. C., Suvannasankha, A., Shah, M. R., Lentzsch, S., Zonder, J. A., Baz, R., Maly, J. J., Namburi, S., Wu, K. L., Pianko, M., Ye, J. C., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Bumma, N. (2023). Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study. Blood, 142(Supplement 1), 4746–4746. https://doi.org/10.1182/blood-2023-177968

Mejia Saldarriaga, M., Unkenholz, C., Fein, J. A., Monge, J., Rosenbaum, C., Pearse, R., Mapara, M., Inghirami, G., Lentzsch, S., Reshef, R., Niesvizky, R., & Bustoros, M. (2023). Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities. Blood, 142(Supplement 1), 3341–3341. https://doi.org/10.1182/blood-2023-187832

Cicero, K. I., Dlamini, X., Mavengere, Y., Justman, J., Nuwagaba-Biribonwoha, H., Dlamini, M., Ngwenyama, S., Ngcamphalala, C., Low, A., Philip, N. M., El-Sadr, W. M., Sahabo, R., Abreha, T., Temesgen, S., Dlamini, S., Mahlalela, N., Chiuzan, C., Chen, Y., Pan, S. S., … Neugut, A. I. (2023). Prevalence of Monoclonal Gammopathy of Undetermined Significance in Eswatini: A Study of an African Population. Blood, 142(Supplement 1), 4767–4767. https://doi.org/10.1182/blood-2023-172435

Biran, N., Dhakal, B., Niesvizky, R., Lentzsch, S., McKay, J. T., Vesole, D. H., Nooka, A. K., Paul, B., Hari, P. N., Stork-Sloots, L., D’Ambrosi, S., Kuiper, R., van Vliet, M., Siegel, D. S., Usmani, S. Z., & van Rhee, F. (2023). Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients. Blood, 142(Supplement 1), 3386–3386. https://doi.org/10.1182/blood-2023-180761

McNerney, K. O., Fabrizio, V. A., Talleur, A. C., Si Lim, S., Dreyzin, A., Baggott, C., Vatsayan, A., Rossoff, J., Prabhu, S., Pacenta, H. L., Phillips, C. L., Talano, J.-A., Moskop, A., Verneris, M. R., Myers, D., Karras, N., Bonifant, C. L., Qayed, M., Hermiston, M. L., … Naik, S. (2023). Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia. Blood, 142(Supplement 1), 2133–2133. https://doi.org/10.1182/blood-2023-189921

Mellgard, G., Gilligan, M., Cliff, E. R. S., Bhutani, D., Mohyuddin, G. R., Eisenberger, A., Lentzsch, S., & Chakraborty, R. (2023). Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM). Blood, 142(Supplement 1), 4768–4768. https://doi.org/10.1182/blood-2023-174908

Lin, W.-H. W., Rodriguez Cortes, J., Aitken, M., Reglero, C., Laurent, A., Cooke, A., Belver, L., Bhagat, G., Rabadan, R., Ferrando, A. A., & Palomero, T. (2023). Role of the S1P Signaling Pathway in the Pathogenesis of Angioimmunoblastic T-Cell Lymphoma. Blood, 142(Supplement 1), 526–526. https://doi.org/10.1182/blood-2023-174090

Chernak, B., Galan-Diez, M., Ali, A. M., Cuesta-Dominguez, A., Chen, Z., Koehnke, T., Majeti, R., Carroll, M., Raza, A., & Kousteni, S. (2023). Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 142(Supplement 1), 4118–4118. https://doi.org/10.1182/blood-2023-174485

Xu, J. J., Chen, Y., Pantazi, J., Fernando, S., Alija, B., Sudunagunta, V., Bhagat, G., Bowman, R. L., & Viny, A. D. (2023). Stag2-Cohesin Loss Attenuates Flt3 ITD Myeloid Blast Expansion Yet Preserves Mutant HSC. Blood, 142(Supplement 1), 2756–2756. https://doi.org/10.1182/blood-2023-190702

Fu, J., Li, S., Liu, G., MA, H., Marcireau, C., Mapara, M., & Lentzsch, S. (2023). Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways. Blood, 142(Supplement 1), 6618–6618. https://doi.org/10.1182/blood-2023-190740

Xu, J. J., Chen, Y., Pantazi, J., Fernando, S., Alija, B., Sudunagunta, V., Bhagat, G., & Viny, A. D. (2023). Synergy of Stag2-Cohesin Loss Results in Expansion of Npm1c-Mutant Hematopoietic Stem and Progenitor Cells. Blood, 142(Supplement 1), 954–954. https://doi.org/10.1182/blood-2023-190627

Salles, G., Park, S. I., Phillips, T. J., Amengual, J. E., Andorsky, D. J., Campbell, P., McKay, P., Leonard, J. P., Chen, Y., Chen, J., Bannerji, R., Kapopara, A., Szanto, A., & Morschhauser, F. (2023). Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up. Blood, 142(Supplement 1), 3035–3035. https://doi.org/10.1182/blood-2023-179910

Orlando, E. H., Gould, P., Cuzzo, B., Ford, M., Chen, Y., Sanjurjo, A., May, B., Tsapepas, D., Leeman-Neill, R. J., Bhagat, G., Dube, G., Morris, H., Arcasoy, S., Latif, F., Martinez, M., Pereira, M., Lipsky, A. H., Sawas, A., Reshef, R., … Amengual, J. E. (2023). The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder. Blood, 142(Supplement 1), 990–990. https://doi.org/10.1182/blood-2023-177823

Muchtar, E., Sanchorawala, V., Hassan, H., Hegenbart, U., Schonland, S., Lee, H. C., Qazilbash, M. H., Kin, A., Houde, C. A., Buadi, F., Dispenzieri, A., Jacob, E. K., Arai, S., MD, M. C., Chakraborty, R., Lentzsch, S., Magen, H., Shkury, E., Sarubbi, C., … Gertz, M. A. (2023). The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients. Blood, 142(Supplement 1), 4784–4784. https://doi.org/10.1182/blood-2023-188115

Defilipp, Z., Kim, H. T., Spyrou, N., Kowalyk, S., Eng, G., Beheshti, R., Baez, J., Ayuk, F. A., Choe, H., Etra, A., Grupp, S., Hexner, E. O., Hogan, W. J., Kitko, C. L., Qayed, M., Reshef, R., Vasova, I., Zeiser, R., Young, R., … Chen, Y.-B. (2023). The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd. Blood, 142(Supplement 1), 3576–3576. https://doi.org/10.1182/blood-2023-182300

Deluca, C., Beyer, M., Drew, H., Murray, J., Massey, J., Koffman, B., Battiato, K., Gribben, J. G., Lamanna, N., & Russomanno, C. (2023). The Value of Collaboration with Patient Advocacy Organizations to Enhance Initiatives Focused on Patient-Centered Care and Improve Outcomes in Chronic Lymphocytic Leukemia. Blood, 142(Supplement 1), 3715–3715. https://doi.org/10.1182/blood-2023-177959

Lipsky, A. H., Hill, B. T., Winter, A., Bachow, S. H., Viny, A. D., Rosenblat, T. L., Jurcic, J., & Lamanna, N. (2023). Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions. Blood, 142(Supplement 1), 3274–3274. https://doi.org/10.1182/blood-2023-189718

DiPersio, J., Cooper, B. W., Suh, H. C., Koura, D., Bernard, L., Shah, N. N., Walter, R. B., Perales, M.-A., Mapara, M., Tamari, R., Loken, M. R., Breitschwerdt, K., Nath, S., Raffel, G. D., & Koehne, G. (2023). Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT). Blood, 142(Supplement 1), 483–483. https://doi.org/10.1182/blood-2023-190037

Xu-Monette, Z. Y., Li, Y., Snyder, T., Yu, T., LU, T., Tzankov, A., Visco, C., Bhagat, G., Qian, W., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F., Go, H., Ponzoni, M., Ferreri, A. J. M., Møller, M., … Young, K. H. (2023). Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 429–429. https://doi.org/10.1182/blood-2023-179972

Biran, N., Dhakal, B., Niesvizky, R., Lentzsch, S., McKay, J. T., Vesole, D. H., Nooka, A. K., Paul, B., Hari, P. N., Stork-Sloots, L., D’Ambrosi, S., Kuiper, R., van Vliet, M., Siegel, D. S., Usmani, S. Z., & van Rhee, F. (2023). Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival. Blood, 142(Supplement 1), 2013–2013. https://doi.org/10.1182/blood-2023-181905